首页 > 最新文献

Iranian Journal of Pharmaceutical Research最新文献

英文 中文
Particle Size Tailoring of Quercetin Nanosuspensions by Wet Media Milling Technique: A Study on Processing and Formulation Parameters. 湿介质研磨法制备槲皮素纳米混悬剂的工艺及配方参数研究。
IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.5812/ijpr-130626
Pegah Cheshmehnoor, Noushin Bolourchian, Erfan Abdollahizad, Arash Derakhshi, Simin Dadashzadeh, Azadeh Haeri

Background: A large number of new substances have insufficient biopharmaceutical properties for oral administration caused by their slow dissolution rate and poor solubility.

Objective: The purpose of our experiment was to improve the physicochemical properties of a hydrophobic drug, quercetin, by the nanomilling approach.

Methods: Quercetin nanosuspensions were prepared using a wet-milling method followed by lyophilization. Stabilizer type and ratio, drug content, milling time, and bead size were identified as critical variables, and their impacts on quercetin particle size were assessed. The optimized nanocrystal was characterized by its morphology, crystallinity, molecular interactions, saturation solubility, and dissolution properties.

Results: At optimized process conditions of milling at 500 rpm for 18 cycles of grinding with 0.3 - 0.4 mm zirconium oxide beads, minimum particle size, and PDI values were 281.21 nm and 0.22, respectively. Nanocrystals showed rod-like nanostructures, and XRD scans confirmed a decrease in drug crystallinity. The optimized formulation showed increased solubility and dissolution rate, as well as good physical stability.

Conclusions: Particle size reduction by media milling technique was an efficient method for the solubility enhancement of hydrophobic drugs.

背景:大量新物质由于溶出速度慢、溶解度差,口服给药的生物制药性能不足。目的:采用纳米研磨的方法改善疏水药物槲皮素的理化性质。方法:采用湿磨法制备槲皮素纳米混悬液,冷冻干燥。确定稳定剂的种类和配比、药物含量、磨粒时间和颗粒大小为关键变量,并评估其对槲皮素粒径的影响。通过形貌、结晶度、分子相互作用、饱和溶解度和溶解性能对优化后的纳米晶体进行了表征。结果:在优化的工艺条件下,转速为500转/分,0.3 ~ 0.4 mm氧化锆珠磨18次,最小粒径为281.21 nm, PDI值为0.22。纳米晶体呈棒状纳米结构,XRD扫描证实药物结晶度下降。优化后的配方具有较高的溶解度和溶出率,良好的物理稳定性。结论:介质磨粒技术是提高疏水药物溶解度的有效方法。
{"title":"Particle Size Tailoring of Quercetin Nanosuspensions by Wet Media Milling Technique: A Study on Processing and Formulation Parameters.","authors":"Pegah Cheshmehnoor,&nbsp;Noushin Bolourchian,&nbsp;Erfan Abdollahizad,&nbsp;Arash Derakhshi,&nbsp;Simin Dadashzadeh,&nbsp;Azadeh Haeri","doi":"10.5812/ijpr-130626","DOIUrl":"https://doi.org/10.5812/ijpr-130626","url":null,"abstract":"<p><strong>Background: </strong>A large number of new substances have insufficient biopharmaceutical properties for oral administration caused by their slow dissolution rate and poor solubility.</p><p><strong>Objective: </strong>The purpose of our experiment was to improve the physicochemical properties of a hydrophobic drug, quercetin, by the nanomilling approach.</p><p><strong>Methods: </strong>Quercetin nanosuspensions were prepared using a wet-milling method followed by lyophilization. Stabilizer type and ratio, drug content, milling time, and bead size were identified as critical variables, and their impacts on quercetin particle size were assessed. The optimized nanocrystal was characterized by its morphology, crystallinity, molecular interactions, saturation solubility, and dissolution properties.</p><p><strong>Results: </strong>At optimized process conditions of milling at 500 rpm for 18 cycles of grinding with 0.3 - 0.4 mm zirconium oxide beads, minimum particle size, and PDI values were 281.21 nm and 0.22, respectively. Nanocrystals showed rod-like nanostructures, and XRD scans confirmed a decrease in drug crystallinity. The optimized formulation showed increased solubility and dissolution rate, as well as good physical stability.</p><p><strong>Conclusions: </strong>Particle size reduction by media milling technique was an efficient method for the solubility enhancement of hydrophobic drugs.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e130626"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/65/60/ijpr-21-1-130626.PMC10007990.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9106081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of the Group Purchasing Structure in the Field of Pharmaceuticals and Medical Devices: The Case of Public Pharmacies. 药品和医疗器械领域的团购结构研究——以公共药房为例。
IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.5812/ijpr-130522
Mohammadreza Rahim, Sajjad Esmaeili, Mohammad Peikanpour

Background: The supply chain of pharmaceuticals and medical devices takes on critical importance regarding group purchasing, given its contribution to a country's healthcare system. One of the primary loops in this chain is the pharmacy as a supplier of goods to consumers and a buyer of goods from distributors.

Objectives: Given the importance of proper and productive preparation, this study examined the structure of aggregated procurement of drugs and medical supplies in public pharmacies.

Methods: This study used a qualitative method and interviews to collect the necessary data. Fourteen experts and specialists in the public pharmacy field were interviewed and selected using the purposive sampling method. Finally, the textual data were analyzed using efficient thematic analysis.

Results: According to experts, the organizational structure for aggregated procurement of medicines and medical supplies in Iran's public pharmacies can take the form of a headquarters structure, a virtual structure, and a semi-centralized virtual structure. The main requirements for these structures are software infrastructure, a productive workforce, and improved storage methods.

Conclusions: According to the majority of experts, the most desirable structure for implementing aggregated procurement in hospital pharmacies is the headquarters structure. The aggregated procurement process can reduce pharmacy costs and increase financial reserves and profitability if adequately implemented and equipped with the necessary infrastructure.

背景:鉴于药品和医疗器械供应链对一个国家卫生保健系统的贡献,它对团购具有至关重要的意义。这个链条的主要循环之一是药房作为消费者的商品供应商和经销商的商品买家。目的:考虑到适当和有效准备的重要性,本研究审查了公共药房药品和医疗用品的集中采购结构。方法:本研究采用定性方法和访谈法收集必要的资料。采用目的抽样的方法,对14名公共药学领域的专家和专家进行了访谈和选择。最后,采用高效的主位分析方法对语篇数据进行分析。结果:据专家介绍,伊朗公共药房药品和医疗用品集中采购的组织结构可以采取总部结构、虚拟结构和半集中式虚拟结构的形式。这些结构的主要需求是软件基础设施、高效的劳动力和改进的存储方法。结论:大多数专家认为医院药房实施集中采购最理想的结构是总部结构。如果充分实施并配备必要的基础设施,综合采购过程可以降低药房成本,增加财务储备和盈利能力。
{"title":"Investigation of the Group Purchasing Structure in the Field of Pharmaceuticals and Medical Devices: The Case of Public Pharmacies.","authors":"Mohammadreza Rahim,&nbsp;Sajjad Esmaeili,&nbsp;Mohammad Peikanpour","doi":"10.5812/ijpr-130522","DOIUrl":"https://doi.org/10.5812/ijpr-130522","url":null,"abstract":"<p><strong>Background: </strong>The supply chain of pharmaceuticals and medical devices takes on critical importance regarding group purchasing, given its contribution to a country's healthcare system. One of the primary loops in this chain is the pharmacy as a supplier of goods to consumers and a buyer of goods from distributors.</p><p><strong>Objectives: </strong>Given the importance of proper and productive preparation, this study examined the structure of aggregated procurement of drugs and medical supplies in public pharmacies.</p><p><strong>Methods: </strong>This study used a qualitative method and interviews to collect the necessary data. Fourteen experts and specialists in the public pharmacy field were interviewed and selected using the purposive sampling method. Finally, the textual data were analyzed using efficient thematic analysis.</p><p><strong>Results: </strong>According to experts, the organizational structure for aggregated procurement of medicines and medical supplies in Iran's public pharmacies can take the form of a headquarters structure, a virtual structure, and a semi-centralized virtual structure. The main requirements for these structures are software infrastructure, a productive workforce, and improved storage methods.</p><p><strong>Conclusions: </strong>According to the majority of experts, the most desirable structure for implementing aggregated procurement in hospital pharmacies is the headquarters structure. The aggregated procurement process can reduce pharmacy costs and increase financial reserves and profitability if adequately implemented and equipped with the necessary infrastructure.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e130522"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/3b/ijpr-21-1-130522.PMC10007992.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9106083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influenza Vaccine and COVID-19 Pandemic: Could This Vaccine Help Limit the Potential Adverse Consequences of SARS-CoV-2? 流感疫苗和COVID-19大流行:这种疫苗能帮助限制SARS-CoV-2的潜在不良后果吗?
IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.5812/ijpr-127032
Reza Mosaed, Hossein Fasihi, Amir Norouzi, Vahid Anjomanian, Mohammad Afshar Ardalan, Farshid Alazmani Noodeh, Ali Reza Khoshdel

The COVID-19 pandemic has prompted researchers to find treatments and vaccines to control SARS-CoV-2. There are some hypotheses about the benefit of respiratory virus vaccines, like MMR, for COVID-19 pneumonia severity, morbidity, and mortality. The influenza vaccine is one of the most frequently used respiratory virus vaccines covered by one of the Iranian insurance institutes. We have a symmetrical group of participants that have received this vaccine that could be compared with each other. We compared 3,379 persons aged 20 - 75 years for the effect of the influenza vaccine on COVID-19 mortality. We ultimately found that it does not affect mortality caused by COVID-19 pneumonia, but it can decrease the hospitalization cost in people over 65 years with a history of chronic disease.

COVID-19大流行促使研究人员寻找控制SARS-CoV-2的治疗方法和疫苗。关于呼吸道病毒疫苗(如MMR)对COVID-19肺炎严重程度、发病率和死亡率的益处,有一些假设。流感疫苗是伊朗一家保险机构承保的最常用的呼吸道病毒疫苗之一。我们有一组对称的参与者,他们接种了这种疫苗,可以相互比较。我们比较了3379名年龄在20 - 75岁之间的人,研究流感疫苗对COVID-19死亡率的影响。我们最终发现,它不会影响COVID-19肺炎引起的死亡率,但它可以降低65岁以上有慢性疾病史的患者的住院费用。
{"title":"Influenza Vaccine and COVID-19 Pandemic: Could This Vaccine Help Limit the Potential Adverse Consequences of SARS-CoV-2?","authors":"Reza Mosaed,&nbsp;Hossein Fasihi,&nbsp;Amir Norouzi,&nbsp;Vahid Anjomanian,&nbsp;Mohammad Afshar Ardalan,&nbsp;Farshid Alazmani Noodeh,&nbsp;Ali Reza Khoshdel","doi":"10.5812/ijpr-127032","DOIUrl":"https://doi.org/10.5812/ijpr-127032","url":null,"abstract":"<p><p>The COVID-19 pandemic has prompted researchers to find treatments and vaccines to control SARS-CoV-2. There are some hypotheses about the benefit of respiratory virus vaccines, like MMR, for COVID-19 pneumonia severity, morbidity, and mortality. The influenza vaccine is one of the most frequently used respiratory virus vaccines covered by one of the Iranian insurance institutes. We have a symmetrical group of participants that have received this vaccine that could be compared with each other. We compared 3,379 persons aged 20 - 75 years for the effect of the influenza vaccine on COVID-19 mortality. We ultimately found that it does not affect mortality caused by COVID-19 pneumonia, but it can decrease the hospitalization cost in people over 65 years with a history of chronic disease.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e127032"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/b3/ijpr-21-1-127032.PMC9872545.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9135327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of Curcumin-Loaded OA400 Nanoparticle's Effect on the Expression of E6 and E7 Human Papilloma-Virus Oncogenes and P53 and Rb Factors in HeLa Cell Line. 姜黄素OA400纳米颗粒对人乳头瘤病毒E6、E7癌基因及P53、Rb因子在HeLa细胞系表达的影响
IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.5812/ijpr-130762
Rezvaneh Vahedian Sadeghi, Masoud Parsania, Majid Sadeghizadeh, Setareh Haghighat

Background: Curcumin, a compound derived from the root of the Curcuma longa, has been confirmed as an anticancer, chemoprotective, and gene/protein regulatory agent. Nanoformulation of curcumin has been developed to increase its targeting efficiency, solubility, controlled release, and physical and chemical stability.

Objectives: This study investigated the effect of new nano-type curcumin, oleic acid-derived dendrosome (OA400 nanoparticles), on the expression of E6 and E7 human papillomavirus oncogenes and P53 and Rb factors in the HeLa cell line. After preparing nano-curcumin by mixing OA400 nano-carrier and curcumin, its effect was considered on the human cervical cancer cell line (HeLa cell line RRID: CVCL_003) and normal fibroblast cells.

Methods: MTT assay and flow cytometry were used to evaluate cell viability and apoptosis. Furthermore, real-time RT-PCR and western blot analyses assessed RNA and protein expression of E6, E7, P53, and Rb. Statistical analyses were performed by GraphPad Prism 7 software.

Results: The nanoformulation of curcumin could reduce the expression of E6 and E7 oncogenes and increase P53 and Rb tumor suppressors in HeLa cancerous cells at 15 μM concentration; however, it had no significant effect on the viability of normal fibroblast cells. On the other hand, curcumin altered the expression of these genes at a 50-μM concentration. Gene and protein expression analysis indicated the up-regulation of P53 and Rb factors and the down-regulation of E6 and E7 under the influence of nano-curcumin treatment more than curcumin.

Conclusions: These data indicate the potential of curcumin-loaded OA400 nanoparticles to be considered as a treatment option in cervical cancer investigations.

背景:姜黄素是一种从姜黄根中提取的化合物,已被证实具有抗癌、化学保护和基因/蛋白质调节作用。为了提高姜黄素的靶向效率、溶解度、缓释度和物理化学稳定性,研究了姜黄素纳米制剂。目的:研究新型纳米型姜黄素油酸衍生树突体(OA400纳米粒子)对人乳头瘤病毒E6、E7癌基因及P53、Rb因子在HeLa细胞株中表达的影响。将OA400纳米载体与姜黄素混合制备纳米姜黄素后,考察其对人宫颈癌细胞系(HeLa细胞系RRID: CVCL_003)和正常成纤维细胞的影响。方法:采用MTT法和流式细胞术检测细胞活力和凋亡情况。此外,实时RT-PCR和western blot分析评估了E6、E7、P53和Rb的RNA和蛋白表达。采用GraphPad Prism 7软件进行统计学分析。结果:姜黄素纳米制剂在15 μM浓度下可降低HeLa癌细胞中E6、E7癌基因的表达,增加P53、Rb抑癌基因的表达;但对正常成纤维细胞的活力无明显影响。另一方面,姜黄素在50 μ m浓度下改变了这些基因的表达。基因和蛋白表达分析表明,纳米姜黄素对P53和Rb因子的上调作用大于姜黄素,对E6和E7的下调作用大于纳米姜黄素。结论:这些数据表明,姜黄素负载的OA400纳米颗粒可能被认为是宫颈癌研究的一种治疗选择。
{"title":"Investigation of Curcumin-Loaded OA400 Nanoparticle's Effect on the Expression of <i>E6</i> and <i>E7</i> Human Papilloma-Virus Oncogenes and <i>P53</i> and <i>Rb</i> Factors in HeLa Cell Line.","authors":"Rezvaneh Vahedian Sadeghi,&nbsp;Masoud Parsania,&nbsp;Majid Sadeghizadeh,&nbsp;Setareh Haghighat","doi":"10.5812/ijpr-130762","DOIUrl":"https://doi.org/10.5812/ijpr-130762","url":null,"abstract":"<p><strong>Background: </strong>Curcumin, a compound derived from the root of the <i>Curcuma longa</i>, has been confirmed as an anticancer, chemoprotective, and gene/protein regulatory agent. Nanoformulation of curcumin has been developed to increase its targeting efficiency, solubility, controlled release, and physical and chemical stability.</p><p><strong>Objectives: </strong>This study investigated the effect of new nano-type curcumin, oleic acid-derived dendrosome (OA400 nanoparticles), on the expression of <i>E6</i> and <i>E7</i> human papillomavirus oncogenes and <i>P53</i> and <i>Rb</i> factors in the HeLa cell line. After preparing nano-curcumin by mixing OA400 nano-carrier and curcumin, its effect was considered on the human cervical cancer cell line (HeLa cell line RRID: CVCL_003) and normal fibroblast cells.</p><p><strong>Methods: </strong>MTT assay and flow cytometry were used to evaluate cell viability and apoptosis. Furthermore, real-time RT-PCR and western blot analyses assessed RNA and protein expression of <i>E6</i>, <i>E7</i>, <i>P53</i>, and <i>Rb</i>. Statistical analyses were performed by GraphPad Prism 7 software.</p><p><strong>Results: </strong>The nanoformulation of curcumin could reduce the expression of <i>E6</i> and <i>E7</i> oncogenes and increase <i>P53</i> and <i>Rb</i> tumor suppressors in HeLa cancerous cells at 15 μM concentration; however, it had no significant effect on the viability of normal fibroblast cells. On the other hand, curcumin altered the expression of these genes at a 50-μM concentration. Gene and protein expression analysis indicated the up-regulation of <i>P53</i> and <i>Rb</i> factors and the down-regulation of <i>E6</i> and <i>E7</i> under the influence of nano-curcumin treatment more than curcumin.</p><p><strong>Conclusions: </strong>These data indicate the potential of curcumin-loaded OA400 nanoparticles to be considered as a treatment option in cervical cancer investigations.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e130762"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/15/e9/ijpr-21-1-130762.PMC9872547.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9135331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying Key Lysosome-Related Genes Associated with Drug-Resistant Breast Cancer Using Computational and Systems Biology Approach. 利用计算和系统生物学方法鉴定与耐药乳腺癌相关的关键溶酶体相关基因。
IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.5812/ijpr-130342
Aref Shiralipour, Babak Khorsand, Leila Jafari, Mohammad Salehi, Mahsa Kazemi, Javad Zahiri, Vahid Jajarmi, Bahram Kazemi

Background: Drug resistance in breast cancer is an unsolved problem in treating patients. It has been recently discussed that lysosomes contribute to the invasion and angiogenesis of cancer cells. There is evidence that lysosomes can also cause multi-drug resistance. We analyzed this emerging concept in breast cancer through computational and systems biology approaches.

Objectives: We aimed to identify the key lysosome-related genes associated with drug-resistant breast cancer.

Methods: All genes contributing to the structure and function of lysosomes were inquired through the Human Lysosome Gene Database. The prioritized top 51 genes from the provided lists of Endeavour, ToppGene, and GPSy as prioritization tools were selected. All lysosomal genes and 12 breast cancer-related genes aligned to identify the most similar genes to breast cancer-related genes. Different centralities were applied to score each human protein to calculate the most central lysosomal genes in the human protein-protein interaction (PPI) network. Common genes were extracted from the results of the mentioned methods as a selected gene set. For Gene Ontology enrichment, the selected gene set was analyzed by WebGestalt, DAVID, and KOBAS. The PPI network was constructed via the STRING database. The PPI network was analyzed utilizing Cytoscape for topology network interaction and CytoHubba to extract hub genes.

Results: Based on biological studies, literature reviews, and comparing all mentioned analyzing methods, six genes were introduced as essential in breast cancer. This computational approach to all lysosome-related genes suggested that candidate genes include PRF1, TLR9, CLTC, GJA1, AP3B1, and RPTOR. The analyses of these six genes suggest that they may have a crucial role in breast cancer development, which has rarely been evaluated. These genes have a potential therapeutic implication for new drug discovery for chemo-resistant breast cancer.

Conclusions: The present work focused on all the functional and structural lysosome-related genes associated with breast cancer. It revealed the top six lysosome hub genes that might serve as therapeutic targets in drug-resistant breast cancer. Since these genes play a pivotal role in the structure and function of lysosomes, targeting them can effectively overcome drug resistance.

背景:乳腺癌耐药是目前治疗中尚未解决的问题。近年来人们讨论溶酶体参与癌细胞的侵袭和血管生成。有证据表明,溶酶体也可引起多重耐药。我们通过计算和系统生物学方法分析了乳腺癌中这一新兴概念。目的:我们旨在鉴定与耐药乳腺癌相关的关键溶酶体相关基因。方法:通过人类溶酶体基因数据库查询所有与溶酶体结构和功能有关的基因。从Endeavour、ToppGene和GPSy提供的列表中选择优先排序的前51个基因作为优先排序工具。所有溶酶体基因和12个乳腺癌相关基因进行比对,以确定与乳腺癌相关基因最相似的基因。应用不同的中心性对每个人类蛋白质进行评分,以计算人类蛋白质-蛋白质相互作用(PPI)网络中最中心的溶酶体基因。从上述方法的结果中提取常见基因作为选定的基因集。对于基因本体的富集,选择的基因集通过WebGestalt、DAVID和KOBAS进行分析。通过STRING数据库构建PPI网络。利用Cytoscape进行拓扑网络相互作用分析,利用CytoHubba提取中心基因。结果:通过生物学研究、文献回顾和对所有分析方法的比较,介绍了6个在乳腺癌中必不可少的基因。这种对所有溶酶体相关基因的计算方法表明,候选基因包括PRF1、TLR9、CLTC、GJA1、AP3B1和RPTOR。对这六个基因的分析表明,它们可能在乳腺癌的发展中起着至关重要的作用,而这一点很少得到评估。这些基因对发现治疗耐药乳腺癌的新药具有潜在的治疗意义。结论:目前研究的重点是与乳腺癌相关的所有功能和结构溶酶体相关基因。它揭示了可能作为耐药乳腺癌治疗靶点的前六个溶酶体中心基因。由于这些基因在溶酶体的结构和功能中起着关键作用,靶向它们可以有效地克服耐药性。
{"title":"Identifying Key Lysosome-Related Genes Associated with Drug-Resistant Breast Cancer Using Computational and Systems Biology Approach.","authors":"Aref Shiralipour,&nbsp;Babak Khorsand,&nbsp;Leila Jafari,&nbsp;Mohammad Salehi,&nbsp;Mahsa Kazemi,&nbsp;Javad Zahiri,&nbsp;Vahid Jajarmi,&nbsp;Bahram Kazemi","doi":"10.5812/ijpr-130342","DOIUrl":"https://doi.org/10.5812/ijpr-130342","url":null,"abstract":"<p><strong>Background: </strong>Drug resistance in breast cancer is an unsolved problem in treating patients. It has been recently discussed that lysosomes contribute to the invasion and angiogenesis of cancer cells. There is evidence that lysosomes can also cause multi-drug resistance. We analyzed this emerging concept in breast cancer through computational and systems biology approaches.</p><p><strong>Objectives: </strong>We aimed to identify the key lysosome-related genes associated with drug-resistant breast cancer.</p><p><strong>Methods: </strong>All genes contributing to the structure and function of lysosomes were inquired through the Human Lysosome Gene Database. The prioritized top 51 genes from the provided lists of Endeavour, ToppGene, and GPSy as prioritization tools were selected. All lysosomal genes and 12 breast cancer-related genes aligned to identify the most similar genes to breast cancer-related genes. Different centralities were applied to score each human protein to calculate the most central lysosomal genes in the human protein-protein interaction (PPI) network. Common genes were extracted from the results of the mentioned methods as a selected gene set. For Gene Ontology enrichment, the selected gene set was analyzed by WebGestalt, DAVID, and KOBAS. The PPI network was constructed via the STRING database. The PPI network was analyzed utilizing Cytoscape for topology network interaction and CytoHubba to extract hub genes.</p><p><strong>Results: </strong>Based on biological studies, literature reviews, and comparing all mentioned analyzing methods, six genes were introduced as essential in breast cancer. This computational approach to all lysosome-related genes suggested that candidate genes include PRF1, TLR9, CLTC, GJA1, AP3B1, and RPTOR. The analyses of these six genes suggest that they may have a crucial role in breast cancer development, which has rarely been evaluated. These genes have a potential therapeutic implication for new drug discovery for chemo-resistant breast cancer.</p><p><strong>Conclusions: </strong>The present work focused on all the functional and structural lysosome-related genes associated with breast cancer. It revealed the top six lysosome hub genes that might serve as therapeutic targets in drug-resistant breast cancer. Since these genes play a pivotal role in the structure and function of lysosomes, targeting them can effectively overcome drug resistance.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e130342"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/71/ijpr-21-1-130342.PMC10007991.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9111094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model. 阻断PD-1/PD-L1相互作用抑制小鼠肿瘤模型。
IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.5812/ijpr-132329
Shima Salehi, Hajarossadat Ghaderi, Mahdi Habibi-Anbouhi, Alireza Shoari, Ayda Hassanzadeh Eskafi, Alireza Sabouri, Mohammad Hosseininejad-Chafi, Arghavan Ashja Ardalan, Behzad Ramezani, Fatemeh Kazemi-Lomedasht, Mahdi Behdani

Background: Overexpression of programmed cell death ligand 1 (PD-L1) in tumor cells and subsequent interaction with the programmed cell death protein 1 (PD-1) in tumor-infiltrating T cells cause an immune evasion of the tumor from cytotoxic T-cells. Therefore, inhibiting such interaction by a recombinant PD-1 can hinder tumor growth and extend the survival rate.

Methods: The mouse extracellular domain of PD-1 (mPD-1) was expressed in E. coli BL21 (DE3) strain and purified using nickel affinity chromatography. The binding ability of the purified protein to human PD-L1 was studied using ELISA. Finally, the tumor-bearing mice were used to evaluate the potential antitumor effect.

Results: The recombinant mPD-1 showed a significant binding capacity to human PD-L1 at the molecular level. The tumor size significantly decreased in the tumor-bearing mice after the intra-tumoral injections of mPD-1. Moreover, the survival rate increased significantly after eight weeks of monitoring. The histopathology revealed the necrosis in the tumor tissue of the control group compared to the mPD-1 received mice.

Conclusions: Our outcomes propose that interaction blockade between PD-1 and PD-L1 is a promising approach for targeted tumor therapy.

背景:肿瘤细胞中程序性细胞死亡配体1 (PD-L1)的过度表达以及随后与肿瘤浸润性T细胞中的程序性细胞死亡蛋白1 (PD-1)的相互作用导致肿瘤对细胞毒性T细胞的免疫逃避。因此,通过重组PD-1抑制这种相互作用可以抑制肿瘤生长,延长生存率。方法:在大肠杆菌BL21 (DE3)中表达小鼠细胞外结构域PD-1 (mPD-1),采用镍亲和层析纯化。用ELISA法研究纯化蛋白与人PD-L1的结合能力。最后,用荷瘤小鼠评价其潜在的抗肿瘤作用。结果:重组蛋白mPD-1在分子水平上与人PD-L1具有明显的结合能力。瘤内注射mPD-1后,荷瘤小鼠的肿瘤大小明显减小。观察8周后存活率明显提高。组织病理学检查显示,与mPD-1组小鼠相比,对照组肿瘤组织出现坏死。结论:我们的研究结果表明,阻断PD-1和PD-L1的相互作用是一种很有希望的靶向肿瘤治疗方法。
{"title":"Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model.","authors":"Shima Salehi,&nbsp;Hajarossadat Ghaderi,&nbsp;Mahdi Habibi-Anbouhi,&nbsp;Alireza Shoari,&nbsp;Ayda Hassanzadeh Eskafi,&nbsp;Alireza Sabouri,&nbsp;Mohammad Hosseininejad-Chafi,&nbsp;Arghavan Ashja Ardalan,&nbsp;Behzad Ramezani,&nbsp;Fatemeh Kazemi-Lomedasht,&nbsp;Mahdi Behdani","doi":"10.5812/ijpr-132329","DOIUrl":"https://doi.org/10.5812/ijpr-132329","url":null,"abstract":"<p><strong>Background: </strong>Overexpression of programmed cell death ligand 1 (PD-L1) in tumor cells and subsequent interaction with the programmed cell death protein 1 (PD-1) in tumor-infiltrating T cells cause an immune evasion of the tumor from cytotoxic T-cells. Therefore, inhibiting such interaction by a recombinant PD-1 can hinder tumor growth and extend the survival rate.</p><p><strong>Methods: </strong>The mouse extracellular domain of PD-1 (mPD-1) was expressed in <i>E. coli</i> BL21 (DE3) strain and purified using nickel affinity chromatography. The binding ability of the purified protein to human PD-L1 was studied using ELISA. Finally, the tumor-bearing mice were used to evaluate the potential antitumor effect.</p><p><strong>Results: </strong>The recombinant mPD-1 showed a significant binding capacity to human PD-L1 at the molecular level. The tumor size significantly decreased in the tumor-bearing mice after the intra-tumoral injections of mPD-1. Moreover, the survival rate increased significantly after eight weeks of monitoring. The histopathology revealed the necrosis in the tumor tissue of the control group compared to the mPD-1 received mice.</p><p><strong>Conclusions: </strong>Our outcomes propose that interaction blockade between PD-1 and PD-L1 is a promising approach for targeted tumor therapy.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e132329"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/3a/ijpr-21-1-132329.PMC9990516.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9438276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Polypharmacy Pattern in Iran: A Comprehensive Analysis of a Large Prescription Database. 伊朗的多种药房模式:对大型处方数据库的综合分析。
IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.5812/ijpr-131304
Reza Ebrahimoghli, Ali Janati, Hojatolah Gharaee, Mir Hossein Aghaei

Background: Polypharmacy is a significant patient safety concern.

Objectives: This study aims to estimate the prevalence of polypharmacy, its continuity and associated factors, and common medication classes among a large outpatient population in East Azerbaijan province, Iran.

Methods: A retrospective prescription data analysis was performed. The cohort included all ≥ 20 years old subjects with at least one prescription filled during the main three-month study period (2020 March 1 - 2020 May 31). Polypharmacy was defined as being exposed to more than four different medications during the main study period, and continuous polypharmacy was defined as being exposed to more than four medications during both the main study period and follow-up period (2020 October 1 - 2020 December 31). The frequency and prevalence of polypharmacy, along with predictive factors, were estimated. We performed multivariate logistic regression and estimated odds ratios (ORs) to investigate the risk factors for polypharmacy.

Results: 307,820 patients included (mean age 49.8 years, 62.9% female, mean drug use 3.7 (SD = 2.6). Polypharmacy was observed in 28.3% (CI: 28.1 - 28.4), of which 36.6% experienced continuous polypharmacy. The odds of being exposed to polypharmacy increased with being female, increasing age, and exposure to chronic conditions. The groups of medications most utilized by polypharmacy patients were those indicated for gastro-esophageal reflux diseases, beta-blocking agents, antidepressants, blood glucose-lowering drugs, and antithrombotic agents.

Conclusions: Strategies should be formulated to inform healthcare policymakers and providers about the magnitude of the polypharmacy phenomenon, associated factors, and the common medication classes involved.

背景:多种用药是一个重要的患者安全问题。目的:本研究旨在估计伊朗东阿塞拜疆省大量门诊人群中多种用药的流行程度、连续性和相关因素以及常见药物类别。方法:回顾性处方资料分析。该队列包括所有≥20岁的受试者,在主要的三个月研究期间(2020年3月1日至2020年5月31日)至少配药一次。多重用药定义为在主要研究期间暴露于四种以上不同药物,持续多重用药定义为在主要研究期间和随访期间(2020年10月1日至2020年12月31日)暴露于四种以上药物。估计了多种用药的频率和流行程度,以及预测因素。我们采用多变量逻辑回归和估计优势比(ORs)来调查多药的危险因素。结果:共纳入307820例患者,平均年龄49.8岁,女性62.9%,平均用药3.7例(SD = 2.6)。28.3% (CI: 28.1 ~ 28.4)患者为多药,其中36.6%持续为多药。暴露于多种药物的几率随着女性、年龄的增长和慢性疾病的暴露而增加。多药患者最常使用的药物是用于胃食管反流疾病的药物、β -阻滞剂、抗抑郁药、降血糖药和抗血栓药。结论:应制定策略,告知卫生保健决策者和提供者有关多药现象的严重性、相关因素和涉及的常见药物类别。
{"title":"Polypharmacy Pattern in Iran: A Comprehensive Analysis of a Large Prescription Database.","authors":"Reza Ebrahimoghli,&nbsp;Ali Janati,&nbsp;Hojatolah Gharaee,&nbsp;Mir Hossein Aghaei","doi":"10.5812/ijpr-131304","DOIUrl":"https://doi.org/10.5812/ijpr-131304","url":null,"abstract":"<p><strong>Background: </strong>Polypharmacy is a significant patient safety concern.</p><p><strong>Objectives: </strong>This study aims to estimate the prevalence of polypharmacy, its continuity and associated factors, and common medication classes among a large outpatient population in East Azerbaijan province, Iran.</p><p><strong>Methods: </strong>A retrospective prescription data analysis was performed. The cohort included all ≥ 20 years old subjects with at least one prescription filled during the main three-month study period (2020 March 1 - 2020 May 31). Polypharmacy was defined as being exposed to more than four different medications during the main study period, and continuous polypharmacy was defined as being exposed to more than four medications during both the main study period and follow-up period (2020 October 1 - 2020 December 31). The frequency and prevalence of polypharmacy, along with predictive factors, were estimated. We performed multivariate logistic regression and estimated odds ratios (ORs) to investigate the risk factors for polypharmacy.</p><p><strong>Results: </strong>307,820 patients included (mean age 49.8 years, 62.9% female, mean drug use 3.7 (SD = 2.6). Polypharmacy was observed in 28.3% (CI: 28.1 - 28.4), of which 36.6% experienced continuous polypharmacy. The odds of being exposed to polypharmacy increased with being female, increasing age, and exposure to chronic conditions. The groups of medications most utilized by polypharmacy patients were those indicated for gastro-esophageal reflux diseases, beta-blocking agents, antidepressants, blood glucose-lowering drugs, and antithrombotic agents.</p><p><strong>Conclusions: </strong>Strategies should be formulated to inform healthcare policymakers and providers about the magnitude of the polypharmacy phenomenon, associated factors, and the common medication classes involved.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e131304"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/5e/ijpr-21-1-131304.PMC10007994.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9106082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19. Favipiravir在小儿COVID-19患者中的安全性和有效性的单中心队列研究
IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.5812/ijpr-127034
Sedigheh Rafiei Tabatabaei, Omid Moradi, Abdollah Karimi, Shahnaz Armin, Alireza Fahimzad, Roxana Mansour Ghanaie, Mahnaz Jamee, Azam Mousavizadeh, Hossein Amini, Bahador Mirrahimi

Background: Coronavirus disease 2019 (COVID-19) affects the pediatric population.

Objectives: Due to limited data, this study aimed to evaluate the safety and efficacy of favipiravir in the hospitalized pediatric population diagnosed with COVID-19.

Methods: The present retrospective cohort study was conducted on pediatric patients aged 1 - 18 years with a diagnosis of COVID-19 admitted to Mofid Children's Hospital, Tehran, Iran. Favipiravir was administrated at a dose of 60 mg/kg/day (max: 3200 mg/day) on the first day and then 23 mg/kg/day (max: 1200 mg/day) for 7 to 14 days. The patients were evaluated regarding the need for invasive mechanical ventilation, intensive care unit admission, duration of hospital stay, and mortality. Safety was measured by the occurrence of related adverse drug reactions (ADRs).

Results: A total of 95 patients were included in the study. Favipiravir was administered to 25 patients. The need for invasive mechanical ventilation was reported in 4 (16.00%) and 11 (15.71%) patients in the favipiravir and control groups, respectively (P = 1.000). The median duration of hospital stays was significantly higher in patients who received favipiravir than in the controls (P = 0.002). No difference was observed in the mortality rate (P = 0.695). The ADRs, including decreased appetite, hypotension, and chest pain, were more prevalent in patients who received favipiravir than in the controls (P < 0.05).

Conclusions: The administration of favipiravir in the pediatric population is associated with higher ADR occurrence with no positive effect on the need for invasive mechanical ventilation, hospital stay, and mortality. Further randomized controlled trials are necessary for better judgment.

背景:2019冠状病毒病(COVID-19)影响儿科人群。目的:由于资料有限,本研究旨在评估favipiravir在诊断为COVID-19的住院儿童人群中的安全性和有效性。方法:本回顾性队列研究对伊朗德黑兰Mofid儿童医院收治的1 - 18岁诊断为COVID-19的儿童患者进行了研究。Favipiravir在第一天以60mg /kg/天(最大剂量:3200mg /天)给药,然后以23mg /kg/天(最大剂量:1200mg /天)给药,持续7至14天。评估患者是否需要有创机械通气、重症监护病房入住情况、住院时间和死亡率。安全性通过相关药物不良反应(adr)的发生来衡量。结果:共纳入95例患者。25例患者给予Favipiravir。favipiravir组和对照组分别有4例(16.00%)和11例(15.71%)患者需要有创机械通气(P = 1.000)。接受favipiravir治疗的患者的中位住院时间明显高于对照组(P = 0.002)。死亡率差异无统计学意义(P = 0.695)。favipiravir组的不良反应发生率高于对照组,包括食欲下降、低血压和胸痛(P < 0.05)。结论:在儿科人群中使用favipiravir与较高的不良反应发生率相关,对有创机械通气需求、住院时间和死亡率无积极影响。进一步的随机对照试验对更好的判断是必要的。
{"title":"A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19.","authors":"Sedigheh Rafiei Tabatabaei,&nbsp;Omid Moradi,&nbsp;Abdollah Karimi,&nbsp;Shahnaz Armin,&nbsp;Alireza Fahimzad,&nbsp;Roxana Mansour Ghanaie,&nbsp;Mahnaz Jamee,&nbsp;Azam Mousavizadeh,&nbsp;Hossein Amini,&nbsp;Bahador Mirrahimi","doi":"10.5812/ijpr-127034","DOIUrl":"https://doi.org/10.5812/ijpr-127034","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) affects the pediatric population.</p><p><strong>Objectives: </strong>Due to limited data, this study aimed to evaluate the safety and efficacy of favipiravir in the hospitalized pediatric population diagnosed with COVID-19.</p><p><strong>Methods: </strong>The present retrospective cohort study was conducted on pediatric patients aged 1 - 18 years with a diagnosis of COVID-19 admitted to Mofid Children's Hospital, Tehran, Iran. Favipiravir was administrated at a dose of 60 mg/kg/day (max: 3200 mg/day) on the first day and then 23 mg/kg/day (max: 1200 mg/day) for 7 to 14 days. The patients were evaluated regarding the need for invasive mechanical ventilation, intensive care unit admission, duration of hospital stay, and mortality. Safety was measured by the occurrence of related adverse drug reactions (ADRs).</p><p><strong>Results: </strong>A total of 95 patients were included in the study. Favipiravir was administered to 25 patients. The need for invasive mechanical ventilation was reported in 4 (16.00%) and 11 (15.71%) patients in the favipiravir and control groups, respectively (P = 1.000). The median duration of hospital stays was significantly higher in patients who received favipiravir than in the controls (P = 0.002). No difference was observed in the mortality rate (P = 0.695). The ADRs, including decreased appetite, hypotension, and chest pain, were more prevalent in patients who received favipiravir than in the controls (P < 0.05).</p><p><strong>Conclusions: </strong>The administration of favipiravir in the pediatric population is associated with higher ADR occurrence with no positive effect on the need for invasive mechanical ventilation, hospital stay, and mortality. Further randomized controlled trials are necessary for better judgment.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e127034"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/94/ijpr-21-1-127034.PMC9872546.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9135329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Portable and Benchtop Near-Infrared Spectrometers for the Detection of Citric Acid-adulterated Lime Juice: A Chemometrics Approach. 便携式和台式近红外光谱仪检测柠檬酸掺假酸橙汁的比较:化学计量学方法。
IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.5812/ijpr-128372
Reza Jahani, Saskia van Ruth, Yannick Weesepoel, Martin Alewijn, Farzad Kobarfard, Mehrdad Faizi, Mohammad Hossain Shojaee AliAbadi, Arash Mahboubi, Azadeh Nasiri, Hassan Yazdanpanah

Background: Since the incidence of food adulteration is rising, finding a rapid, accurate, precise, low-cost, user-friendly, high-throughput, ruggedized, and ideally portable method is valuable to combat food fraud. Near-infrared spectroscopy (NIRS), in combination with a chemometrics-based approach, allows potentially rapid, frequent, and in situ measurements in supply chains.

Methods: This study focused on the feasibility of a benchtop Fourier-transformation-NIRS apparatus (FT-NIRS, 1000 - 2500 nm) and a portable short wave NIRS device (SW-NIRS, 740 - 1070 nm) for the discrimination of genuine and citric acid-adulterated lime juice samples in a cost-effective manner following chemometrics study.

Results: Principal component analysis (PCA) of the spectral data resulted in a noticeable distinction between genuine and adulterated samples. Wavelengths between 1100 - 1400 nm and ‎‎1550 - 1900 nm were found to be more important for the discrimination of samples for the benchtop FT-NIRS data, while variables between 950 - 1050 nm contributed significantly to the discrimination of samples based on the portable SW-NIRS data. Following partial least squares discriminant analysis (PLS-DA) as a discriminant model, standard normal variate (SNV) or multiplicative scatter correction (MSC) transformation of benchtop FT-NIRS data and SNV in combination with the second derivative transformation of portable SW-NIRS data on the training set delivered equal accuracy (94%) in the prediction of the test set. In the soft independent modeling of class analogy (SIMCA) as a class-modeling approach, the overall performances of generated models on the auto-scaled data were 98% and 94.5% for benchtop FT-NIRS and portable SW-NIRS, respectively.

Conclusions: As a proof of concept, NIRS technology coupled with appropriate ‎multivariate classification models enables fast detection of citric acid-adulterated ‎lime juices. In addition, the promising results of portable SW-NIRS combined with SIMCA indicated its use as a screening tool for on-site analysis of lime juices at various stages of the food supply chain.

背景:随着食品掺假事件的不断增加,寻找一种快速、准确、精密、低成本、用户友好、高通量、坚固耐用、理想便携的方法对打击食品欺诈具有重要意义。近红外光谱(NIRS)与基于化学计量学的方法相结合,可以在供应链中进行快速、频繁和现场测量。方法:通过化学计量学研究,探讨了台式傅里叶变换近红外光谱仪(FT-NIRS, 1000 ~ 2500 nm)和便携式短波近红外光谱仪(sww -NIRS, 740 ~ 1070 nm)鉴别柠檬酸掺假酸橙汁样品的可行性。结果:光谱数据的主成分分析(PCA)导致正品和掺假样品之间的显著区别。在台式FT-NIRS数据中,1100 ~ 1400 nm和1550 ~ 1900 nm之间的波长对样品的区分更为重要,而在便携式ss - nirs数据中,950 ~ 1050 nm之间的变量对样品的区分有显著影响。将偏最小二乘判别分析(PLS-DA)作为判别模型,将台式FT-NIRS数据和SNV的标准正态变量(SNV)或乘法散点校正(MSC)变换与便携式SW-NIRS数据在训练集上的二阶导数变换相结合,在测试集的预测中获得相同的准确度(94%)。在类类比的软独立建模(SIMCA)方法中,台式FT-NIRS和便携式SW-NIRS在自动缩放数据上生成的模型的总体性能分别为98%和94.5%。结论:作为概念验证,近红外光谱技术结合适当的多元分类模型可以快速检测柠檬酸掺假酸橙汁。此外,便携式SW-NIRS结合SIMCA的结果表明,它可以作为食品供应链各个阶段酸橙汁现场分析的筛选工具。
{"title":"Comparison of Portable and Benchtop Near-Infrared Spectrometers for the Detection of Citric Acid-adulterated Lime Juice: A Chemometrics Approach.","authors":"Reza Jahani,&nbsp;Saskia van Ruth,&nbsp;Yannick Weesepoel,&nbsp;Martin Alewijn,&nbsp;Farzad Kobarfard,&nbsp;Mehrdad Faizi,&nbsp;Mohammad Hossain Shojaee AliAbadi,&nbsp;Arash Mahboubi,&nbsp;Azadeh Nasiri,&nbsp;Hassan Yazdanpanah","doi":"10.5812/ijpr-128372","DOIUrl":"https://doi.org/10.5812/ijpr-128372","url":null,"abstract":"<p><strong>Background: </strong>Since the incidence of food adulteration is rising, finding a rapid, accurate, precise, low-cost, user-friendly, high-throughput, ruggedized, and ideally portable method is valuable to combat food fraud. Near-infrared spectroscopy (NIRS), in combination with a chemometrics-based approach, allows potentially rapid, frequent, and in situ measurements in supply chains.</p><p><strong>Methods: </strong>This study focused on the feasibility of a benchtop Fourier-transformation-NIRS apparatus (FT-NIRS, 1000 - 2500 nm) and a portable short wave NIRS device (SW-NIRS, 740 - 1070 nm) for the discrimination of genuine and citric acid-adulterated lime juice samples in a cost-effective manner following chemometrics study.</p><p><strong>Results: </strong>Principal component analysis (PCA) of the spectral data resulted in a noticeable distinction between genuine and adulterated samples. Wavelengths between 1100 - 1400 nm and ‎‎1550 - 1900 nm were found to be more important for the discrimination of samples for the benchtop FT-NIRS data, while variables between 950 - 1050 nm contributed significantly to the discrimination of samples based on the portable SW-NIRS data. Following partial least squares discriminant analysis (PLS-DA) as a discriminant model, standard normal variate (SNV) or multiplicative scatter correction (MSC) transformation of benchtop FT-NIRS data and SNV in combination with the second derivative transformation of portable SW-NIRS data on the training set delivered equal accuracy (94%) in the prediction of the test set. In the soft independent modeling of class analogy (SIMCA) as a class-modeling approach, the overall performances of generated models on the auto-scaled data were 98% and 94.5% for benchtop FT-NIRS and portable SW-NIRS, respectively.</p><p><strong>Conclusions: </strong>As a proof of concept, NIRS technology coupled with appropriate ‎multivariate classification models enables fast detection of citric acid-adulterated ‎lime juices. In addition, the promising results of portable SW-NIRS combined with SIMCA indicated its use as a screening tool for on-site analysis of lime juices at various stages of the food supply chain.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e128372"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/82/ijpr-21-1-128372.PMC10024328.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9156679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polysaccharide Peptide Induced Colorectal Cancer Cells Apoptosis by Down-Regulating EGFR and PD-L1 Expression. 多糖肽下调EGFR和PD-L1表达诱导结直肠癌细胞凋亡
IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-12-01 DOI: 10.5812/ijpr-123909
Lin Jian, He Zhicheng, Liu Shubai

Background: Colorectal cancer (CRC) is the most frequent death-causing disease in the world. The Trametes versicolor mushroom, a traditional Chinese medicine, has been used as anti-cancer medicine with long history. Its cultured mycelia extracts, namely polysaccharide peptide (PSP) as the major active component in Trametes versicolor, is widely used in eastern countries to stimulate the immune system and treat deadly cancers, including CRC.

Methods: This study aimed to explore the mechanism through which PSP inhibits CRC cells proliferation. In vitro, cell proliferation and cytotoxicity of PSP were assessed using human CRC cell lines (HCT116 and HT29). The real-time polymerase chain reaction (PCR), western blot, and immunofluorescence methods were used to examine the expression of epidermal growth factor receptor (EGFR), programmed cell death-ligand 1 (PD-L1), activator of transcription 3 (STAT3), c-Jun, and NF-κB in the PSP treated CRC cells. Human peripheral blood mononuclear cells (PBMC), which were activated with CD3/CD28/CD2 T cell activator and interleukin 2 (IL-2), were co-cultured with HCT116, which was pre-treated with PSP to reduce PD-L1 expression. The synergic effect of T-cells killing was evaluated using the terminal-deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) method.

Results: Polysaccharide peptide significantly inhibited proliferation of HCT116 and HT29 cell line in vitro. Polysaccharide peptide strongly reduced the expression and phosphorylation level of EGFR. In addition, PSP pretreatment significantly decreased the expression of downstream molecules PD-L1 and EGFR signaling pathways (c-Jun and STAT3) in HCT116. Polysaccharide peptide pretreatment enhanced the T-cells killing effect induced by co-culture PBMC on HCT116 cells.

Conclusions: Polysaccharide peptide may be used as a prophylactic and therapeutic agent against CRC via down-regulating PD-L1 and EGFR signaling pathway.

背景:结直肠癌(CRC)是世界上最常见的致死疾病。彩曲菌是一种传统的中药,作为抗癌药物有着悠久的历史。其培养的菌丝体提取物,即多糖肽(PSP),在东方国家被广泛用于刺激免疫系统和治疗致命的癌症,包括结直肠癌。方法:本研究旨在探讨PSP抑制结直肠癌细胞增殖的机制。在体外,用人结直肠癌细胞系(HCT116和HT29)评估PSP的细胞增殖和细胞毒性。采用实时聚合酶链反应(PCR)、western blot和免疫荧光法检测PSP处理的结直肠癌细胞中表皮生长因子受体(EGFR)、程序性细胞死亡配体1 (PD-L1)、转录激活因子3 (STAT3)、c-Jun和NF-κB的表达。用CD3/CD28/CD2 T细胞激活剂和白细胞介素2 (IL-2)激活的人外周血单核细胞(PBMC)与HCT116共培养,HCT116经PSP预处理后降低PD-L1的表达。使用末端脱氧核苷酸转移酶介导的镍端标记(TUNEL)方法评估t细胞杀伤的协同效应。结果:多糖肽对HCT116和HT29细胞株体外增殖有明显抑制作用。多糖肽能显著降低EGFR的表达和磷酸化水平。此外,PSP预处理显著降低HCT116中下游分子PD-L1和EGFR信号通路(c-Jun和STAT3)的表达。多糖肽预处理可增强共培养PBMC对HCT116细胞的杀伤作用。结论:多糖肽可能通过下调PD-L1和EGFR信号通路作为预防和治疗结直肠癌的药物。
{"title":"Polysaccharide Peptide Induced Colorectal Cancer Cells Apoptosis by Down-Regulating <i>EGFR</i> and <i>PD-L1</i> Expression.","authors":"Lin Jian,&nbsp;He Zhicheng,&nbsp;Liu Shubai","doi":"10.5812/ijpr-123909","DOIUrl":"https://doi.org/10.5812/ijpr-123909","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is the most frequent death-causing disease in the world. The <i>Trametes versicolor</i> mushroom, a traditional Chinese medicine, has been used as anti-cancer medicine with long history. Its cultured mycelia extracts, namely polysaccharide peptide (PSP) as the major active component in <i>Trametes versicolor</i>, is widely used in eastern countries to stimulate the immune system and treat deadly cancers, including CRC.</p><p><strong>Methods: </strong>This study aimed to explore the mechanism through which PSP inhibits CRC cells proliferation. In vitro, cell proliferation and cytotoxicity of PSP were assessed using human CRC cell lines (HCT116 and HT29). The real-time polymerase chain reaction (PCR), western blot, and immunofluorescence methods were used to examine the expression of epidermal growth factor receptor (<i>EGFR</i>), programmed cell death-ligand 1 (<i>PD-L1</i>), activator of transcription 3 (<i>STAT3</i>), <i>c-Jun</i>, and <i>NF-κB</i> in the PSP treated CRC cells. Human peripheral blood mononuclear cells (PBMC), which were activated with CD3/CD28/CD2 T cell activator and interleukin 2 (IL-2), were co-cultured with HCT116, which was pre-treated with PSP to reduce <i>PD-L1</i> expression. The synergic effect of T-cells killing was evaluated using the terminal-deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) method.</p><p><strong>Results: </strong>Polysaccharide peptide significantly inhibited proliferation of HCT116 and HT29 cell line in vitro. Polysaccharide peptide strongly reduced the expression and phosphorylation level of <i>EGFR</i>. In addition, PSP pretreatment significantly decreased the expression of downstream molecules <i>PD-L1</i> and <i>EGFR</i> signaling pathways (<i>c-Jun</i> and <i>STAT3</i>) in HCT116. Polysaccharide peptide pretreatment enhanced the T-cells killing effect induced by co-culture PBMC on HCT116 cells.</p><p><strong>Conclusions: </strong>Polysaccharide peptide may be used as a prophylactic and therapeutic agent against CRC via down-regulating <i>PD-L1</i> and <i>EGFR</i> signaling pathway.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"21 1","pages":"e123909"},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/f2/ijpr-21-1-123909.PMC10024323.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9156681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Iranian Journal of Pharmaceutical Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1